Active Ingredients (In Each 15 Ml)
Guaifenesin 100 mg ................................................ Expectorant
Dextromethorphan.............................................. Cough Suppressant
The following Structured Product Label (SPL) was submitted to the FDA by Menper Distributors Inc. for the product Bisolvine (NDC 53145-322). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredients (in each 15 ml), purpose, uses, warnings:, do not:, keep out of reach of children, directions, other safety information, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Guaifenesin 100 mg ................................................ Expectorant
Dextromethorphan.............................................. Cough Suppressant
Expectorant
Cough Suppressant
temporarily relieves cough due to minor throat and bronchial irritation as may occur with the common cold and helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive.
Do not exceed recommended dosage.
A persistent cough may be a sign of a serious condition. If cough persists for more than one week, tends to recur, or is accompanied by fever, rash, or persistent headache, consult a doctor.
In case of accidental overdose, seek professional assisstance or contact a Poison Control Center immediately.
Age | Dose |
| Children 6 to under 12 years of age | 1 teaspoonful (15 mL) every 4 hours |
| Children 2 to under 6 years of age | 1/2 teaspoonful (7.5 mL) every 4 hours |
| Children under 2 years of age | Consult your doctor |
store this product between 15° to 30° C (59°-86° F)
artificial strawberryt-banana flavor, citric acid, fd&c red #40, glycerin, methylparaben, propylene glycol, propylparaben, puridied water, sucrose.
1-800-560-5223 M-F 9 AM to 4 PM Eastern.
* Please review the disclaimer below.